JP2524990B2 - 長時間作用製剤 - Google Patents

長時間作用製剤

Info

Publication number
JP2524990B2
JP2524990B2 JP62021668A JP2166887A JP2524990B2 JP 2524990 B2 JP2524990 B2 JP 2524990B2 JP 62021668 A JP62021668 A JP 62021668A JP 2166887 A JP2166887 A JP 2166887A JP 2524990 B2 JP2524990 B2 JP 2524990B2
Authority
JP
Japan
Prior art keywords
calcium channel
alkyl
pharmaceutical composition
channel blocker
long
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP62021668A
Other languages
English (en)
Japanese (ja)
Other versions
JPS62252732A (ja
Inventor
カルム・ブレチン・マクファーレーン
アラステア・ブレアトン・セルカーク
マイケル・ジョン・デイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Syntex USA LLC
Original Assignee
Syntex USA LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntex USA LLC filed Critical Syntex USA LLC
Publication of JPS62252732A publication Critical patent/JPS62252732A/ja
Application granted granted Critical
Publication of JP2524990B2 publication Critical patent/JP2524990B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/82—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP62021668A 1986-01-30 1987-01-29 長時間作用製剤 Expired - Lifetime JP2524990B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US82389686A 1986-01-30 1986-01-30
US823896 1986-01-30
US94087886A 1986-12-10 1986-12-10
US940878 1986-12-10

Publications (2)

Publication Number Publication Date
JPS62252732A JPS62252732A (ja) 1987-11-04
JP2524990B2 true JP2524990B2 (ja) 1996-08-14

Family

ID=27124769

Family Applications (1)

Application Number Title Priority Date Filing Date
JP62021668A Expired - Lifetime JP2524990B2 (ja) 1986-01-30 1987-01-29 長時間作用製剤

Country Status (18)

Country Link
EP (1) EP0231026B1 (enExample)
JP (1) JP2524990B2 (enExample)
KR (1) KR900005009B1 (enExample)
AU (1) AU604672B2 (enExample)
CA (1) CA1285227C (enExample)
DE (1) DE3782439T2 (enExample)
DK (1) DK175216B1 (enExample)
ES (1) ES2052500T3 (enExample)
FI (1) FI88872C (enExample)
GR (1) GR3006148T3 (enExample)
HU (1) HU196709B (enExample)
IE (1) IE61879B1 (enExample)
IL (2) IL81419A0 (enExample)
IT (1) IT1206876B (enExample)
NO (1) NO174325C (enExample)
NZ (1) NZ219090A (enExample)
PH (1) PH26366A (enExample)
PT (1) PT84213B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4940556A (en) * 1986-01-30 1990-07-10 Syntex (U.S.A.) Inc. Method of preparing long acting formulation
IE63321B1 (en) * 1986-02-03 1995-04-05 Elan Corp Plc Drug delivery system
GB2209669B (en) * 1987-09-11 1992-02-12 Squibb & Sons Inc Pharmaceutical composition containing high drug load and method for preparing same
JP2528706B2 (ja) * 1988-05-30 1996-08-28 ゼリア新薬工業株式会社 ジヒドロピリジン化合物の製剤組成物
US4925676A (en) * 1989-02-02 1990-05-15 Warner-Lambert Company Extended release gemfibrozil composition
HU203041B (en) * 1989-03-14 1991-05-28 Egyt Gyogyszervegyeszeti Gyar Process for producing pharmaceutical compositions of controlled releasing factor containing nifedipin
JPH0729926B2 (ja) * 1989-07-25 1995-04-05 大塚製薬株式会社 易吸収性製剤用組成物
EP0619731B1 (en) * 1991-12-30 2000-10-04 Fmc Corporation Microcrystalline cellulose spheronization composition
GB9203689D0 (en) * 1992-02-20 1992-04-08 Euro Celtique Sa Pharmaceutical composition
EP0557064B1 (en) * 1992-02-20 1997-06-11 Euroceltique S.A. Modified release formulation
HRP970485A2 (en) * 1996-09-13 1998-08-31 Joerg Rosenberg Process for producing solid pharmaceutical forms
US6303607B1 (en) * 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
US6479496B1 (en) * 1998-09-10 2002-11-12 Cv Therapeutics, Inc. Methods for treating angina with ranolazine
ATE400251T1 (de) 1999-02-09 2008-07-15 Pfizer Prod Inc Zusammensetzungen basischer arzneistoffe mit verbesserter bioverfügbarkeit
US20090208579A1 (en) * 2004-12-27 2009-08-20 Eisai R & D Management Co., Ltd. Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
US8481565B2 (en) 2004-12-27 2013-07-09 Eisai R&D Management Co., Ltd. Method for stabilizing anti-dementia drug

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE795766A (fr) * 1972-02-22 1973-08-22 Lilly Co Eli Particules de napsylate de propoxyphene retard et procede de fabrication de ces particules
JPS5846019A (ja) * 1981-09-14 1983-03-17 Kanebo Ltd 持続性ニフエジピン製剤
FR2581541B1 (fr) * 1985-05-09 1988-05-20 Rhone Poulenc Sante Nouvelles compositions pharmaceutiques permettant la liberation prolongee d'un principe actif et leur procede de preparation

Also Published As

Publication number Publication date
FI88872C (fi) 1993-07-26
IE61879B1 (en) 1994-11-30
FI870380L (fi) 1987-07-31
NO870368D0 (no) 1987-01-29
IE870229L (en) 1987-07-30
EP0231026B1 (en) 1992-11-04
PT84213B (pt) 1989-03-30
ES2052500T3 (es) 1994-07-16
PT84213A (en) 1987-02-01
FI870380A0 (fi) 1987-01-29
NO174325B (no) 1994-01-10
IT1206876B (it) 1989-05-11
AU6810287A (en) 1987-08-06
HUT42950A (en) 1987-09-28
NO870368L (no) 1987-07-31
IL81419A0 (en) 1987-08-31
DK47787A (da) 1987-07-31
DK47787D0 (da) 1987-01-29
NZ219090A (en) 1990-04-26
AU604672B2 (en) 1991-01-03
KR870007121A (ko) 1987-08-17
NO174325C (no) 1994-04-20
JPS62252732A (ja) 1987-11-04
KR900005009B1 (ko) 1990-07-16
EP0231026A1 (en) 1987-08-05
IL81419A (en) 1991-07-18
HU196709B (en) 1989-01-30
PH26366A (en) 1992-06-01
DE3782439D1 (de) 1992-12-10
FI88872B (fi) 1993-04-15
DK175216B1 (da) 2004-07-12
IT8767057A0 (it) 1987-01-29
DE3782439T2 (de) 1993-05-19
CA1285227C (en) 1991-06-25
GR3006148T3 (enExample) 1993-06-21

Similar Documents

Publication Publication Date Title
US5198226A (en) Long acting nicardipine hydrochloride formulation
US4940556A (en) Method of preparing long acting formulation
US5209933A (en) Long acting calcium channel blocker composition
CA2396380C (en) Improved pharmaceutical compositions for poorly soluble drugs
JP2637981B2 (ja) 吸収制御薬剤組成物
CA1312286C (en) Pharmaceutical preparation containing metoprolol
JP4852423B2 (ja) 固体の経口投与可能な医薬組成物の製造方法
KR900005009B1 (ko) 지속성 서방출형 약제학적 조성물
EP1039909A1 (en) Method and composition of an oral preparation of itraconazole
HU197839B (en) Process for producing metoprolol containing pharmaceutical compositions
JP2005526738A (ja) 低溶解度の薬物を経口投与するための投与剤形
JP2003504331A (ja) フェノフィブレート含有医薬組成物およびこれを調製するための方法
JP2011241218A (ja) ｐＨ非依存延長放出性医薬組成物
JPH05178747A (ja) ジルチアゼム処方剤
JP2863528B2 (ja) ジルチアゼムを含有する徐放性製剤の製造方法
JP3110794B2 (ja) １，４−ジヒドロピリジン誘導体を含有する製剤
WO1989002738A1 (en) Sustained-release nifedipine formulation
WO2001076557A1 (en) Sustained release preparations
PT1178780E (pt) Formulações de inibidores selectivos da reassimilação de serotonina, de libertação controlada e multiparticularidades
PT2001445E (pt) Esferoides farmacêuticos
JPH10120571A (ja) 塩酸ジルチアゼム徐放性製剤
EP3764983A1 (en) A sustained release formulation comprising acemetacin with bimodal in vitro release
TW202304433A (zh) 硝苯地平美托洛爾緩釋組合物、其製備方法及應用
JP2001513100A (ja) デクスフェンフルラミンのプログラムされた放出のための製薬学的組成物
JPWO2001076557A1 (ja) 徐放性製剤

Legal Events

Date Code Title Description
R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term